Roughly 37,000 women with advanced breast cancer in the United States currently have no good treatment options after their disease progresses on standard first-line therapy. In four days, the FDA could change that.
The agency faces a July 17, 2026 deadline to decide whether to approve gedatolisib, an investigational drug developed by Celcuity, for patients with hormone receptor-positive, HER2-negative, PIK3CA wild-type advanced breast cancer. The drug received both Priority Review and Breakthrough Therapy designation from the FDA — two designations the agency reserves for therapies addressing serious unmet medical needs.
If approved, gedatolisib would be the first treatment specifically indicated for PIK3CA wild-type patients — a distinction that matters enormously to oncologists and patients alike. All currently approved PI3K inhibitors work only in patients whose tumors carry a PIK3CA mutation. For patients whose tumors do not carry that mutation, those drugs offer no clinical benefit whatsoever.
Why This Matters
HR-positive, HER2-negative breast cancer is the most common breast cancer subtype. It accounts for approximately two-thirds of all breast cancer cases, according to Managed Healthcare Executive, and typically responds well to first-line hormonal therapies combined with CDK4/6 inhibitors.
The problem comes at the second line — when the disease progresses after that initial treatment. At that point, patients are genotyped, and their options diverge sharply based on whether their tumor carries a mutation in the PIK3CA gene.
For patients whose tumors carry PIK3CA mutations, approved PI3K inhibitors like alpelisib (Piqray) are available options. But for patients whose tumors are PIK3CA wild-type — meaning no mutation in that gene — existing PI3K inhibitors simply do not work. That is approximately 60 percent of second-line HR-positive breast cancer cases, or roughly 37,000 patients per year in the United States.
For those 37,000 patients, the current options after CDK4/6 inhibitor failure are limited, and outcomes in this setting are poor. The FDA's July 17 decision is, for many of them, directly personal.
What We Know So Far
The New Drug Application for gedatolisib is supported by data from the Phase 3 VIKTORIA-1 trial, specifically the PIK3CA wild-type cohort. The trial, identified on ClinicalTrials.gov as NCT05501886, enrolled patients with HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer who had progressed on or after treatment with both a CDK4/6 inhibitor and an aromatase inhibitor.
The trial compared two gedatolisib-based regimens against fulvestrant monotherapy — the current standard-of-care option for this population:
- Gedatolisib plus palbociclib plus fulvestrant (the triplet regimen): median progression-free survival of 9.3 months , compared to 2.0 months for fulvestrant alone — a 76 percent reduction in the risk of disease progression or death
- Gedatolisib plus fulvestrant (the doublet regimen): median progression-free survival of 7.4 months — a 67 percent reduction in the risk of disease progression or death
Both results were statistically significant. The full VIKTORIA-1 PIK3CA wild-type cohort data were published in the Journal of Clinical Oncology on March 9, 2026.
The New Drug Application was submitted under the FDA's Real-Time Oncology Review program, which is designed to facilitate shorter review periods for serious conditions.
Where the Need Is Greatest
HR-positive, HER2-negative advanced breast cancer affects patients across all U.S. regions and all demographic groups, but the burden of advanced disease falls disproportionately on patients with limited access to academic cancer centers offering clinical trials.
For patients in rural areas, smaller metro markets, and communities with limited oncology infrastructure, the availability of an approved drug can mean the difference between receiving guideline-consistent treatment and watching the disease progress on a regimen that is not optimal.
The PIK3CA wild-type population is also notable because this group has historically been underserved by targeted oncology research. Nearly two decades of PI3K inhibitor development was focused on patients with PIK3CA mutations — and patients without those mutations were largely excluded from consideration for that therapeutic class. Gedatolisib's mechanism is different in a clinically important way: it targets all four Class I PI3K isoforms, as well as mTORC1 and mTORC2, rather than a single isoform. That multi-target approach is what makes it active in patients regardless of PIK3CA mutation status.
What Doctors and Experts Say
Igor Gorbatchevsky, MD, chief medical officer of Celcuity, said in the Journal of Clinical Oncology publication announcement that the efficacy data from the VIKTORIA-1 PIK3CA wild-type cohort represent an important addition to the clinical evidence in this disease setting. He described the findings as potentially practice changing for patients with limited options.
Brian Sullivan, CEO and co-founder of Celcuity, noted that researchers have sought for nearly 20 years to develop a drug that blockades the PI3K/AKT/mTOR pathway comprehensively without inducing unacceptable levels of toxicity. He said the VIKTORIA-1 results validate that approach.
John Kraus, MD, PhD, executive vice president and chief medical officer of Otsuka Pharmaceutical — commenting in a broader oncology context — noted that ADHD manifests differently across patients, highlighting the importance of having multiple therapeutic approaches available. The same principle applies acutely in advanced breast cancer, where molecular heterogeneity between patients makes single-mechanism drugs insufficient for the full population.
What the Evidence Shows and What It Does Not
The VIKTORIA-1 trial was a randomized, controlled Phase 3 study with pre-specified primary endpoints. The results for both gedatolisib regimens were statistically significant and clinically meaningful. The FDA has reviewed these data and accepted the NDA — a step that indicates the submission is complete and the agency considers the data sufficient to support a review.
MedicalDaily Evidence Check
- Study type: Phase 3 randomized controlled trial (VIKTORIA-1, NCT05501886)
- Published in: Journal of Clinical Oncology, March 9, 2026
- Population: HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer after CDK4/6 inhibitor and aromatase inhibitor failure
- What it found: Gedatolisib triplet reduced progression or death by 76% vs. fulvestrant; doublet reduced it by 67%
- Safety: Grade 3 or higher adverse events included neutropenia (62.3% triplet), stomatitis (19.2% triplet), rash, hyperglycemia, and diarrhea; treatment discontinuation rates were low (2.3% triplet, 3.1% doublet)
- What it did not prove: Overall survival benefit has not yet been reported; longer-term follow-up is ongoing
- What readers should know: FDA approval is not guaranteed even with strong Phase 3 data; the PDUFA date of July 17 is a decision deadline, not a guaranteed approval date
Who Would Benefit Most?
If gedatolisib is approved, the patients most likely to benefit include:
- Women with HR-positive, HER2-negative advanced breast cancer whose tumors are PIK3CA wild-type
- Patients who have already progressed on a CDK4/6 inhibitor and an aromatase inhibitor — the standard first-line regimen
- Patients for whom existing PI3K inhibitors were never a viable option due to their tumor's PIK3CA wild-type status
- Patients who have limited or no access to clinical trials offering experimental alternatives
PIK3CA wild-type status is determined through tumor genomic testing, which is increasingly standard in the workup of advanced breast cancer patients at academic cancer centers. Patients who have not had molecular testing of their tumor should discuss this with their oncologist regardless of the FDA's decision.
Symptoms and Warning Signs to Watch For
This article covers a regulatory approval story and does not involve a new outbreak or acute exposure risk. However, patients currently managing HR-positive, HER2-negative advanced breast cancer should be aware of signs that their current treatment may be failing.
Potential signs of disease progression that warrant prompt oncology consultation include:
- New or worsening bone pain
- Shortness of breath or chest discomfort
- Significant new fatigue not explained by treatment
- Swelling or new lumps
- Neurological changes, including headache, visual disturbances, or confusion
Do not self-diagnose. These symptoms are not specific to any one condition. Any concerning change in symptoms should be discussed with an oncologist promptly.
What You Can Do Now
- If you or a family member has HR-positive, HER2-negative advanced breast cancer, ask your oncologist whether your tumor has been tested for PIK3CA mutation status. This testing is essential to understanding which treatments may be appropriate.
- If you are PIK3CA wild-type and have progressed on first-line CDK4/6 inhibitor therapy, ask whether gedatolisib clinical trials or compassionate use options are available pending the FDA's decision.
- Monitor the FDA's drug approval announcements page on July 17, 2026, for news of the decision.
- Patients who lack access to comprehensive tumor genomic profiling may be able to obtain it through academic cancer centers, the NCI Cancer Information Service , or patient advocacy programs through organizations like Susan G. Komen or the Metastatic Breast Cancer Alliance .
- MedicalDaily will publish a same-day update when the FDA issues its decision.
Cost and Access: What Patients Should Know
If gedatolisib is approved, its cost and insurance coverage status will not be immediately clear. Specialty cancer drugs launched in recent years have carried annual costs ranging from $100,000 to more than $200,000 before discounts and copay assistance. Patients without adequate insurance coverage should ask about:
- Patient assistance programs, which Celcuity may offer at launch
- Medicaid coverage for cancer drugs, which varies by state
- 340B drug pricing programs at qualifying hospital systems
- Financial navigation services available through most major cancer centers
The Patient Advocate Foundation and Cancer Care both offer co-pay assistance and financial guidance for cancer patients. Coverage decisions by major insurers typically follow FDA approval by 30 to 90 days. Patients should contact their insurer's specialty pharmacy unit once approval is confirmed.
What Happens Next
The FDA's decision deadline is July 17, 2026 — four days from publication of this article. The agency may approve the drug, approve it with conditions, issue a Complete Response Letter requesting additional data, or, in rare cases, extend its review. There is no public advisory committee meeting scheduled for this application, which some analysts interpret as a sign that the FDA did not require additional outside expert input before making its decision.
If approved, Celcuity will need to complete commercial manufacturing and launch activities. Typical timelines from FDA approval to commercial availability range from several weeks to a few months.
MedicalDaily will update this article on or immediately after July 17, 2026, with the FDA's decision.
The Bottom Line
Gedatolisib has four days until the FDA issues a decision that could open an entirely new treatment path for approximately 37,000 women per year with advanced breast cancer who currently have no standard targeted option after first-line therapy fails. The Phase 3 trial data are strong. The FDA designations — Priority Review and Breakthrough Therapy — reflect the agency's recognition of the unmet need this drug addresses. Whether or not approval is granted on July 17, the arrival of gedatolisib in the regulatory pipeline represents a meaningful scientific step forward for a patient population that has been excluded from the targeted therapy revolution in breast cancer for nearly two decades.
